No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
NVS240621C95000
- 10.50
- -0.27-2.51%
15min DelayClose Jun 18 16:00 ET
10.50High10.50Low
10.50Open10.77Pre Close1 Volume103 Open Interest95.00Strike Price1.05KTurnover120.47%IV0.53%PremiumJun 21, 2024Expiry Date9.94Intrinsic Value100Multiplier1DDays to Expiry0.56Extrinsic Value100Contract SizeAmericanOptions Type0.8841Delta0.0215Gamma9.99Leverage Ratio-0.4338Theta0.0043Rho8.84Eff Leverage0.0147Vega
Intraday
- 5D
- Daily
News
MorphoSys Delisting From Frankfurt Stock Exchange, Nasdaq Expected to Take Place in 3Q
MorphoSys Delisting From Frankfurt Stock Exchange, Nasdaq Expected to Take Place in 3Q
Novartis Delisting Offer Is In Line With Price of Acquisition Closed in May
Novartis Delisting Offer Is In Line With Price of Acquisition Closed in May
Novartis to Offer EUR68 a Share in Cash to Minority MorphoSys Shareholders
Novartis to Offer EUR68 a Share in Cash to Minority MorphoSys Shareholders
Novartis Holds Around 91.04% of MorphoSys as of Thursday
Novartis Holds Around 91.04% of MorphoSys as of Thursday
Novartis to Start Squeeze-Out of MorphoSys' Minority Shareholders
Novartis to Start Squeeze-Out of MorphoSys' Minority Shareholders
Ionis (IONS) Expands Licensing Deal With Otsuka for HAE Drug
Comments
Keep an eye on these recently announced M&As: 👀
$Merck & Co(MRK.US$ to acquire EyeBio
$Biogen(BIIB.US$ to acquire HI-Bio™
$Johnson & Johnson(JNJ.US$ to acquire Proteologix
OnKure, Inc. merger with $Reneo Pharmaceuticals(RPHM.US$
$Novartis AG(NVS.US$ to acquire Mariana Oncology
What companies will be next? 🤔
$Merck & Co(MRK.US$ to acquire EyeBio
$Biogen(BIIB.US$ to acquire HI-Bio™
$Johnson & Johnson(JNJ.US$ to acquire Proteologix
OnKure, Inc. merger with $Reneo Pharmaceuticals(RPHM.US$
$Novartis AG(NVS.US$ to acquire Mariana Oncology
What companies will be next? 🤔
3
$Esperion Therapeutics(ESPR.US$ Multiple sources indicate that Esperion's advancements and commercial success with its cholesterol-lowering drugs, NEXLIZET and NEXLETOL, have positioned it as defininte acquistion target for larger pharmaceutical companies. Esperion's drugs NEXLIZET and NEXLETOL now have primary prevention labels, NEXLIZET will soon become the drug of choice over a PCSK9 inhibitor says Texas based HeartPlace leading Cardio...
12
Stories you might have missed ![]()
Singapore’s private home sales down nearly half in February; 149 condos sold amid holiday lull
DEVELOPERS in Singapore sold 149 private homes in February, 47 per cent fewer than the 281 units moved in January, data released on Friday (Mar 15) by the Urban Redevelopment Authority showed.
Novartis invests US$256 million to expand Singapore plant
SWISS biopharma giant Novartis has invested US$256 million to expand its biopharm...
Singapore’s private home sales down nearly half in February; 149 condos sold amid holiday lull
DEVELOPERS in Singapore sold 149 private homes in February, 47 per cent fewer than the 281 units moved in January, data released on Friday (Mar 15) by the Urban Redevelopment Authority showed.
Novartis invests US$256 million to expand Singapore plant
SWISS biopharma giant Novartis has invested US$256 million to expand its biopharm...
7
Google's disappointing ad sales growth and AMD's lower revenue guidance have hurt investor sentiment, causing their shares to drop. Byron Allen's offer to acquire Paramount Global is seen as beneficial for shareholders, boosting its share price. Novartis AG's lower Q4 earnings and adjusted mid-term guidance have led to a share price decline.
JPMorgan analysts predict a strong uptake for Novartis's various treatments to boost the company's top line, with cost savings from restructuring aiding the bottom line. Morgan Stanley analysts note Novartis's need for external innovation to meet long-term growth ambitions.
Read more